Balchem Corporation (NASDAQ: BCPC) — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited, prepared under U.S. GAAP. Balchem develops and sells specialty ingredients and products. Its reportable segments are Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $239.7 million | $232.5 million | +3.1% |
| Gross margin | $81.5 million; 34.0% | $73.2 million; 31.5% | +11.4%; +2.5 percentage points |
| Operating expenses | $39.8 million | $38.8 million | +2.8% |
| Operating earnings / margin | $41.7 million / 17.4% | $34.4 million / 14.8% | +21.1%; +2.6 percentage points |
| Net earnings | $29.0 million | $22.7 million | +27.6% |
| Diluted EPS | $0.89 | $0.70 | +27.1% |
| Operating cash flow | $33.4 million | $34.8 million | −4.2% |
| Capital expenditures and intangible assets acquired | $6.9 million | $9.7 million | Down $2.8 million |
Gross-margin improvement reflected higher sales and lower cost of sales, primarily from lower manufacturing input costs. Operating expenses rose mainly due to higher compensation costs and the absence of a prior-year asset-sale gain, partly offset by lower transaction and integration expenses. The effective tax rate was 21.3%, versus 22.0%.
Segment results
- Human Nutrition & Health: Sales of $152.7 million, up 15.1%; operating earnings of $33.3 million, up 80.4%. Growth was primarily driven by minerals and nutrients, with volume and mix contributing 13.7% to sales growth.
- Animal Nutrition & Health: Sales of $53.9 million, down 16.9%; operating earnings of $2.1 million, down 78.3%. Lower sales in monogastric and ruminant markets, including lower prices and volume/mix, drove the decline.
- Specialty Products: Sales of $31.6 million, down 1.9%; operating earnings of $8.2 million, up 3.2%. Lower plant nutrition sales were partly offset by higher performance gases sales.
Financial position and liquidity
- At March 31, 2024, cash was $60.3 million, total assets $1.589 billion, and total liabilities $509.9 million. Working capital was $200.4 million, compared with $165.8 million at year-end 2023.
- Revolving debt was $301.6 million, down from $309.6 million at December 31, 2023. The $550 million facility matures July 27, 2027; $248.4 million was available. The stated borrowing rate was 6.554%. Balchem reported compliance with its financial covenants.
- Cash provided by operations was $33.4 million; investing used $6.7 million and financing used $30.0 million. Cash declined $4.1 million during the quarter. Financing included $25.6 million of dividend payments and $8.0 million of net revolving-loan repayments.
- Cash held by foreign subsidiaries was $52.9 million; the company intends to reinvest these funds abroad and notes that repatriation could result in additional withholding taxes.
- A 100-basis-point change in interest rates would change annual interest expense and cash flow by approximately $3.0 million, based on quarter-end borrowings.
Outlook, risks and notable matters
- The filing gives no specific revenue, earnings, or margin guidance. Management expects operating cash flow to fund working capital and necessary capital investments, and says it is pursuing acquisition candidates; additional borrowing or capital-market access may be used if needed.
- Management cautions that sales may fluctuate with macroeconomic conditions, competition, customer preferences, and new-product execution. Disclosed risks also include input costs and availability, foreign exchange and interest rates, manufacturing reliability, cybersecurity, regulation, litigation, and customer and product-related risks.
- At the Verona, Missouri facility, the company is participating in an EPA-supervised investigation concerning potential 1,4-dioxane and chlorobenzene sources at a Superfund site. DOJ discussions also concern alleged Risk Management Plan Rule violations following an EPA inspection. Balchem recorded a probable, reasonably estimable loss contingency that it says is not material; the ultimate outcome and any additional exposure are not quantified in the filing.
- Foreign-currency translation produced a $12.7 million first-quarter loss in other comprehensive income, compared with $9.4 million of income a year earlier. Comprehensive income was $16.4 million, down from $31.7 million.
- There were no impairment charges, no derivatives outstanding at quarter-end, and no material changes to the risk factors identified in the 2023 Form 10-K. Management reported effective disclosure controls and no material change in internal controls.
Important facts for investors to verify
- Whether Human Nutrition & Health growth can continue and whether Animal Nutrition & Health sales and profitability stabilize.
- How much of the margin improvement is sustainable if manufacturing input costs, pricing, or product mix change.
- Cash conversion and working-capital trends, given operating cash flow declined despite higher earnings.
- Debt repayment capacity, variable-rate exposure, and compliance with credit-facility covenants.
- Potential costs, timing, and indemnity coverage associated with the Verona environmental investigation and DOJ discussions.
- Availability and intended use of foreign-held cash, and any tax cost if funds are repatriated.